Indometacin Mcc (Indometacin)

Indometacin works by non‑selectively blocking cyclooxygenase enzymes (COX‑1 and COX‑2), which reduces the formation of prostaglandins—key mediators of inflammation, pain, and fever—thereby providing analgesic and anti‑inflammatory effects.

The exact dose and frequency of Indometacin Mcc are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Indometacin Mcc in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk, and breastfeeding mothers should consult their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Indometacin is a potent non‑selective NSAID with strong anti‑inflammatory activity, often considered more effective for gout attacks compared with some other NSAIDs. However, its gastrointestinal and renal risk profile may be higher, so clinicians weigh benefits against potential adverse effects when selecting therapy.

Indometacin Mcc suppositories should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and direct sunlight. Do not store in extreme heat or humidity to maintain product stability.

Indometacin Mcc is supplied as a rectal suppository. The suppository is inserted into the rectum, typically after bowel movements, following the specific instructions provided by the healthcare professional to ensure proper absorption.

Serious risks include gastrointestinal ulceration or bleeding, acute renal impairment, severe liver injury, and hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Indometacin Mcc should be avoided in individuals with known hypersensitivity to indometacin or other NSAIDs, active gastrointestinal ulcer or bleeding, severe renal or hepatic impairment, and in patients where NSAID use is contraindicated, such as certain cardiovascular conditions.